Kezar Life Sciences to Participate in Three Upcoming September 2023 Investor Conferences

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Company will participate in three upcoming investor conferences taking place in September:
  • Event: 2023 Wells Fargo Healthcare Conference
    Location: Boston, MA
    Date/Time: Thursday, September 7, 2023, at 12:45 pm ET
    Presenter: Noreen R. Henig, M.D., Chief Medical Officer
    Format: Fireside Chat
  • Event: Morgan Stanley 21st Annual Global Healthcare Conference
    Location: New York, NY
    Date/Time: Tuesday, September 12, 2023, at 10:50 am ET
    Presenter: John Fowler, Co-Founder and Chief Executive Officer
    Format: Fireside Chat
  • Event: H.C. Wainwright 25th Annual Global Investment Conference
    Location: New York, NY
    Date/Time: Wednesday, September 13, 2023, at 12:30 pm ET
    Presenter: John Fowler, Co-Founder and Chief Executive Officer
    Format: Podium Presentation

Webcasts from the presentations will be available on the “Events & Presentations” section of the Company’s website at www.kezarlifesciences.com. Following the events, archived webcasts will be available on the Kezar website for 90 days.

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biopharmaceutical company discovering and developing novel treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function to inhibit multiple drivers of disease via single, powerful targets. Zetomipzomib, its lead development asset, is a selective immunoproteasome inhibitor that has completed a Phase 2 clinical trial in lupus nephritis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. KZR-261 is the first anti-cancer clinical candidate from the company’s platform targeting the Sec61 translocon and the protein secretion pathway. An open-label dose-escalation Phase 1 clinical trial of KZR-261 to assess safety, tolerability and preliminary tumor activity in solid tumors is underway. For more information, visit www.kezarlifesciences.com and follow us on LinkedIn, Facebook, Twitter and Instagram.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230831496066/en/

Contacts

Investor Contact:
Gitanjali Jain
Vice President, Investor Relations and External Affairs
gjain@kezarbio.com

Media Contact:
Will Zasadny
Evoke Canale
will.zasadny@evokegroup.com

Source: Kezar Life Sciences, Inc.

Back to news